TEL-AVIV, Israel–(BUSINESS WIRE)–Aspect Imaging is presenting its advanced line of compact MRIs specialized for preclinical research, as well as a brand new integrated simultaneous PET-MRI at WMIC.
Category: Business
Global Safety Goggles and Glasses Market Growth of 3.66% CAGR by 2020 – Analysis, Technologies & Forecasts Report 2016-2020 – Key Vendors: Radians, Sellstrom, MCR Safety – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Safety Goggles and Glasses Market 2016-2020” report to their offering. The report forecasts the global safety goggles and glasses market to grow at a CAGR of 3.66% …
Second Sight to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, will present at the Rodman & Renshaw 18th Annual Global Investment Conference being held September 11-13, 2016. Second Sight’s Chairman, Dr. Robert Greenberg, will host one-on-one meetings throughout the day on Monday, September 12, 2016 and Tuesday, Sept
RetroSense Therapeutics Secures Exclusive Worldwide Rights to ReaChR Optogene from the University of California San Diego
ANN ARBOR, Mich.–(BUSINESS WIRE)–RetroSense Therapeutics LLC, a privately-held, clinical-stage biopharmaceutical company, today announced the Company has signed a worldwide license with the University of California San Diego to secure exclusive rights to develop red activatable channelrhodopsin (ReaChR), a next-generation optogene developed by the late Nobel Laureate Roger Y. Tsien, Ph.D. Financial terms were not disclosed. “The ReaChR license allows us to continue building on our world-leadi
Lucas ELENA annonce la création de la société Eyenostics SAS
LA GAUDE, France–(BUSINESS WIRE)–Eyenostics est une société de recherche sous contrat (CRO) dédiée à la recherche et l’analyse de biomarqueurs oculaires. Elle opère dans les études Clinique et Préclinique en utilisant les méthodes de cytométrie de flux et de RT-qPCR. Grâce à ses employés expérimentés, ses partenaires et ses liens avec un consultant de renom, Eyenostics a pour ambition de devenir le partenaire privilégié des laboratoires pharmaceutiques et sociétés de biotechnologie désireux d
Founder & Former CEO of Advantica Eyecare, Richard L. Sanchez, Joins the Argus Dental & Vision, Inc. Leadership Team
TAMPA, Fla.–(BUSINESS WIRE)–Argus Dental & Vision, Inc. announces that Richard L. Sanchez, former CEO and Founder of Advantica Eyecare, has joined the Argus Leadership Team as Executive Vice President of Strategic Alliances.
National Vision Inc. Announces 2016 College Scholarship Recipients
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Inc., one of the nation’s largest optical retailers providing comprehensive, quality, affordable eye care and vision health, is pleased to announce it has selected five outstanding students as recipients of the 2016 National Vision Inc. College Scholarship Program. Recipients will receive $2,500 to fund the advancement of their education. The award is renewable for up to three years for a total scholarship of $10,000 per student. “We are proud to co
$26 Billion Global Ophthalmology Drugs Market to 2022 – Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Ophthalmology Drugs Market to 2022 – Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period” report to their offering. Globa…
Gobiquity Secures $6M in Series B Funding and Achieves Over 100,000 Children Screened
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–GobiquityTM, a global leader in mobile vision screening technology, received a $6M investment round from venture capital firm InterWest Partners in a first close of its Series B financing. The venture capital firm’s increased commitment will support the company’s commercial growth, specifically its product development and global expansion. In 2015, Gobiquity launched GoCheck Kids™, the world’s first and only comprehensive mobile vision screener that combines
Glaukos Announces Participation in Baird Healthcare Conference
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
Europe Age-related Macular Degeneration Market and Competitive Landscape Highlights Report 2016 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Europe Age-related Macular Degeneration Market and Competitive Landscape Highlights – 2016” report to their offering. Europe Age-related Macular Degeneration Market and Co…
Europe Allergic Conjunctivitis Market and Competitive Pipeline Landscape Highlights 2010-2020 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Europe Allergic Conjunctivitis Market and Competitive Landscape Highlights – 2016” report to their offering. Europe Allergic Conjunctivitis Market and Competitive Landscap…
Global Optical Encoder Industry Analysis and Opportunity Assessment 2016-2026 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Optical Encoder Market: Global Industry Analysis and Opportunity Assessment, 2016-2026” report to their offering. The research report provides a detailed analysis and iden…
Alegeus Announces Support for Expansion of SIGIS IIAS Standard to Include Vision
WALTHAM, Mass.–(BUSINESS WIRE)–Alegeus announced its support for a proposed enhancement to the widely-used Inventory Information Approval System (IIAS) – created and maintained by SIGIS.
Presbia Acquires Comprehensive Patent Portfolio for the Presbia Flexivue Microlens™
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced that on August 2, 2016, its wholly-owned subsidiary, Presbia Ireland, Ltd., completed the purchase of the assets of Neoptics AG (“Neoptics”), including its intellectual property portfolio. “The acquisition of Neoptics’ assets, including its patent portfolio, consolidates the principal intellectual property (‘IP’) and ‘know-how’ underpinning the use of an optically p
Oculis Completes Series A Financing
REYKJAVIK, Iceland–(BUSINESS WIRE)–Oculis announced today the close of a Series A financing round, led by Brunnur Ventures and Silfurberg. The new capital will support continued development of the company’s patented solubilizing nanoparticle (SNP) drug delivery platform and the company’s drug candidates, including the first topical eye-drops for treatment of diabetic macular edema. SNP Drug Delivery Platform – breakthrough in eye-drop technology Oculis’ SNP platform technology is specifically
Eleven Biotherapeutics Completes Exclusive Licensing Deal for IL-6 Antagonist Antibody Technology, Including EBI-031
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven has granted Roche an exclusive, worldwide license to develop and commercialize EBI-031 and all other IL-6 antagonist antibody technology owned by Eleven.
Resumen: Oculis completa ronda de financiación de serie A
REYKJAVIK, Islandia–(BUSINESS WIRE)–Oculis ha anunciado hoy el cierre de una ronda de financiación de serie A, encabezada por Brunnur Ventures y Silfurberg. El nuevo capital ayudará al desarrollo continuado de la plataforma patentada de administración de fármacos de la empresa para nanopartículas solubilizantes (SNP) y los candidatos a fármacos de la empresa, incluidas las primeras gotas oftálmicas tópicas para el tratamiento del edema macular diabético. La plataforma de SNP de Oculis ha sido
Oculis schließt Serie-A-Finanzierung ab
REYKJAVIK, Island–(BUSINESS WIRE)–Oculis meldete heute den Abschluss einer Serie-A-Finanzierungsrunde unter der Leitung von Brunnur Ventures und Silfurberg. Das frische Kapital dient der Förderung der fortgesetzten Entwicklung der patentierten Drug Delivery Platform von Oculis für solubilisierende Nanopartikel (SNP) und der Arzneimittelkandidaten des Unternehmens, einschließlich der ersten topischen Augentropfen zur Behandlung des diabetischen Makulaödems (DME). SNP Drug Delivery Platform – D
Riassunto: Oculis completa il finanziamento di Serie A
REYKJAVIK, Islanda–(BUSINESS WIRE)–Oculis ha annunciato oggi la chiusura del round di finanziamenti di Serie A, condotta da Brunnur Ventures e Silfurberg. Il nuovo capitale servirà a finanziare lo sviluppo continuo della piattaforma di rilascio dei farmaci a base di nanoparticelle solubilizzanti (solubilizing nanoparticle, SNP) brevetto esclusivo della società, e dei candidati farmaci prodotti dall’azienda, compreso il primo trattamento topico a base di collirio per l’edema maculare diabetico